PB43D
Alzheimer's Disease
PreclinicalActive
Key Facts
About Phanes Biotech
Phanes Biotech is an early-stage biotech company targeting the massive and growing unmet medical need in Alzheimer's disease. The company is advancing a dual-platform strategy, with its lead candidate, P021, a small molecule designed to promote neuroregeneration, and PB43D, a tau immunotherapy aimed at a key pathological hallmark of the disease. Founded and led by a team with deep neuroscience expertise, including renowned Alzheimer's researcher Dr. Khalid Iqbal, the company is positioned in the high-risk, high-reward space of disease-modifying Alzheimer's therapies, operating in a fiercely competitive landscape dominated by large pharmaceutical companies.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |